

1 **Supplementary Table 1: Rescue data for 15 recurrent and metastatic male breast cancer cases.**

Case	Transfer, age (years)	DFS (month)	Time of recurrence	Metastatic site	First-line	Best response*	PFS (month)	Second-line	Best response	PFS (month)	Third-line	Best response
1†	63	53	October 2011	Lung, bone, lymph nodes, and chest wall	GnRHa + letrozole	PR	>122	First-line ongoing				
2	43	42	June 25, 2012	Lung and bone	GnRHa + anastrozole	SD	22	T-GnRHa + exemestane	PR–SD	3.5–9	T-GnRHa + exemestane	SD–SD
3	59	47	September 19, 2014	Brain‡, lung, and adrenal gland	GnRHa + letrozole	PD	1	GnRHa + exemestane	SD	5	TP–NP§	SD–SD
4†	65	76	November 6, 2017	Lung and lymph nodes	GnRHa + letrozole	PR	>50	First-line ongoing				

5	65	53	May 17, 2017	Lymph nodes and bones	GnRHa + anastrozole	SD	10	Death by accident			
6	57	12	May 16, 2015	Liver	GnRHa + anastrozole	PD	1	TX	SD	2	Abandon treatment
7	46	60	August 4, 2008	Liver, lung, lymph nodes, and bone	GnRHa + anastrozole	SD	38	GnRHa + fulvestrant	SD	9	Paclitaxel + toremifene SD-NA
8	59	45	December 23, 2014	Liver, spleen, bone marrow, and bone	GnRHa + letrozole	SD	48	Treatment not continued after progression			
9+	69	166	January 16, 2017	Lung and pleura	GnRHa + letrozole	SD	>58	First-line ongoing			
10	64	0	September 2016	Lung and bone	GnRHa + exemestane	SD	12	NX-X	PR-SD	5-7	Interrupt treatment

11	51	0	June 5, 2017	Distant lymph node	TE-GnRH a + letrozole	PR-SD	4-14	NX	SD	8	GnRHa + fulvestrant	SD
12	72	21	May 1, 2018	Bone	GnRHa + anastrozole	SD	24	GnRHa + f ulvestrant	SD	12	NA	NA
13	49	41	March 2015	Liver, lung, brain, <sup>‡</sup> and bone	GnRHa + letrozole	SD	12	GnRHa + f ulvestrant	SD	8	TX-X	SD-SD
14	65	10	February 22, 2019	Lung, adrenal gland, bone, and lymph nodes	GnRHa + anastrozole	SD	9	NA				
15	60	14	September 2018	Lung, pleura, bone, and lymph nodes	TX-GnRH a + anastrozole + pa lbociclib	SD-PR	4-12	N + anloti nib-anloti nib	SD-SD	5.5	NA	NA

1 \*Assessed according to RECIST1.1

1 †Endocrine therapy is ongoing.

2 ‡The brain metastases of Cases 3 and 13 underwent surgical resection and whole-brain radiotherapy separately.

3 §The docetaxel was adjusted to vinorelbine due to diarrhea. Chemotherapy was discontinued due to the gastrointestinal response of cisplatin.

4 GnRHa = Goserelin; N = Vinorelbine; P = Cisplatin; T = Docetaxel; X = Capecitabine.

5 DFS: Disease-free survival; GnRH: Gonadotropin-releasing hormone; GnRHa: GnRH analog; PD: Progressive disease; PR: Partial regression;

6 RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1; SD: Stable disease.

7

8